Going to Tri-Con Next Week?

Written by: Anna Israyelyan, MD, PhD
Manager, Clinical Affairs

Published on:
February 17th, 2017

Anna Israyelyan, MD, PhD
Dr. Israyelyan joined CGI in 2015. She has over 15 years of extensive cancer research and management experience in industry and academia covering wide range of medical areas, including basic, translational, and clinical research. Anna is an active member of the American Society of Hematology (ASH), the American Association for Cancer Research (AACR), and American Association for the Advancement of Science (AAAS). Dr. Israyelyan has a scientific advisory role with matrix management of scientific, technical, and operational aspects related to various biopharma projects and collaborations involving biomarkers in solid tumors and hematologic malignancies.

If you are part of the diagnostics and drug discovery ecosystem, the Tri-Conference ranks as one of the must attend events of the year. The week-long event is scheduled to kick off this Sunday, February 19th, in beautiful San Francisco.

With a 24 year history of delivering molecular medicine and diagnostics breakthroughs and technologies, the International Molecular Med Tri-Conference will host 3,500+ drug discovery and development professionals from over 40 countries…a 20% increase in attendance over the past 5 years.

 

 

 

 

 

 

Consistent with our bench-to-bedside mission, Cancer Genetics, Inc. (CGI) is attending this prime event to meet with various partners, clients, and colleagues to discuss partnerships, biopharma clinical trial service projects, and IVD and CDx development opportunities.

Would you like to meet?  If so, please drop me an email to arrange a meeting.  See you there!


CGI EXPERTS AT TRI-CON 2017

 

 Leslie Abad, MS
Sr Director, Biopharma Market Development & Collaborations
leslie.abad@cgix.com

 

Rob Fannon, MPH, MBA
VP, Biopharma Solutions
rob.fannon@cgix.com

 

Anna Israyelyan, MD, PhD
Clinical Affairs Manager
Anna.Israyelyan@cgix.com
Tel: 323.224.3900 x175

You can also connect with me on LinkedIn.

Comments

comments